A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)

PHASE2TerminatedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

Atacicept

Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.

DRUG

Atacicept

Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.

DRUG

Atacicept

Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.

DRUG

Placebo matched to atacicept

Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.

Trial Locations (50)

Unknown

Research Site, Phoenix

Research Site, Atlanta

Research Site, Northbrook

Research Site, East Lansing

Research Site, Jefferson

Research Site, Cleveland

Philadelphia

Research Site, Nashville

Research Site, Box Hill

Research Site, Fitzroy

Research Site, New Lambton

Research Site, Woodville

Research Site, Innsbruck

Research Site, Diepenbeek

Research Site, Sijsele

Research Site, Calgary

Research Site, Ottawa

Research Site, Ontario

Research Site, Brno

Research Site, Hradec Králové

Research Site, Olomouc

Research Site, Caen

Research Site, Saint-Herblain

Research Site, Bochum

Research Site, Düsseldorf

Research Site, Beirut

Research Site, Kaunas

Research Site, Breda

Research Site, Nieuwegein

Research Site, Rotterdam

Research Site, Dnipropetrovsk

Research Site, Moscow

Research Site, Novosibirsk

Research Site, Saint Petersburg

Research Site, Samara

Research Site, Vladimir

Research Site, Yaroslavl

Research Site, Yekaterinburg

Research Site, Barcelona

Research Site, Madrid

Research Site, Málaga

Research Site, Stockholm

Research Site, Basel

Research Site, Kharkiv

Research Site, Kyiv

Research Site, Odesa

Research Site, Uzhhorod

Research Site, London

Research Site, Sheffield

Research Site, Stoke-on-Trent

Sponsors

Lead Sponsor

All Listed Sponsors
lead

EMD Serono

INDUSTRY

NCT00642902 - A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) | Biotech Hunter | Biotech Hunter